< 首頁 - 合作夥伴 - 臨床試驗受託機構 - 友霖生技醫藥股份有限公司
臨床試驗受託機構

友霖生技醫藥股份有限公司 Orient Pharma Co., Ltd.

卓越成果

Orient Pharma (OP) is the subsidiary of Orient Europharma (OEP), focusing on R&D and manufacturing, and was established on Feb 1, 2008.

OP’s Clinical Research Operation (CRO) Department, established in Mar 2010, provides clinical study related services to help external partners and study sponsors whether in Taiwan or overseas countries (US, EU, Japan, etc.) to directly conduct multi-nation and multi-center early phase (Phase I ~ Phase III) clinical studies in Taiwan, Singapore and Hong Kong according to ICH GCP, study protocol, sponsor’s SOPs and applicable regulations.

  1. Taiwan clinical research organization (CRO) list, certified by Industrial Development Bureau, Ministry of Economic Affairs on 04 Jan 2013
  2. Managed and monitored multi-nation, multi-center clinical study:
    Phase I ~ III TFDA or FDA or EMA IND studies in therapeutic areas including: Breast Cancer, NSCLC, Pancreatic Cancer, Head and Neck Cancer, Bladder Cancer, Type 2 Diabetes Mellitus, Hypertension, Hypercholesterolemia, Insomnia, Attention Deficit Hyperactivity Disorder, Sialorrhea, Asthma, Tuberculosis, Acne Vulgaris, Intradialysis Hypotension, etc.
  3. Passed Singapore Health Sciences Authority (HSA) GCP site inspection on 19-20 May 2014
  4. The Yunlin plant:
  • PIC/S GMP approval from TFDA in July 2011
  • cGMP site inspection by US FDA in April 2013
  • Received “Accreditation Certificate of Foreign Drug Manufacturer” from Japan Ministry of Health, Labor, and Welfare (MHLW) in April 2012

專長服務項目

  • Provide monitoring services for clinical study in Taiwan, Singapore and Hong Kong
  • Manage Phase I~III clinical projects in Asian countries
  • Conduct GCP audit
  • Complete IRB or EC’s required process for clinical trial application
  • Source comparator and perform study specific labeling for IMP

提供實驗室服務

國際認證

財團法人醫藥品查驗中心 T : 請至聯絡我們留言